(PHILADELPHIA) – Coronary artery disease (CAD) is the single largest cause of death in adults in the United States. Until recently, the genetic basis of CAD has been largely unknown, with just a few proven genes (typically genes for cholesterol disorders) accounting for very little of the disease in the population. Now, a new study from researchers at the University of Pennsylvania School of Medicine shows that certain genetic profiles increase risk of coronary artery disease (CAD) while others uniquely increase risk of heart attacks in those with CAD. The findings, published online first today and in an upcoming edition of The Lancet, are the results of the analysis of two genome-wide association studies (GWAS) -- an examination of all or most of the genes (the genome) of different individuals to identify common genetic factors that influence disease.
Lead author Muredach P. Reilly, MBBCH, MSCE, associate professor of Medicine and Pharmacology at Penn, and colleagues compared 12,393 individuals with CAD disorder with 7,383 controls who did not have CAD to identify loci that predispose to angiographic CAD. To identify loci that predispose to heart attacks, they compared 5,783 patients who had angiographic CAD and had a heart attack with 3,644 who had angiographic CAD but no heart attack.
The researchers identified a new locus, ADAMTS7 (a gene already implicated in arthritis), which increased the risk of developing CAD. In the heart-attack comparison, the authors found a new association at the ABO blood group locus. They found that the same gene that codes for the enzyme behind people being blood group O offered protection against heart attacks.
For more information, please see the Lancet’s press release on the study.
http://www.eurekalert.org/pub_releases/2011-01/l-cgp011311.php
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.